Greg Nogle has had an extensive history within the market access field and is currently the vice President of Market Access for Ambry Genetics, a Tempus company. In this role, he is responsible for leading the team in integrating coverage initiatives with CMS/Medicare contractors and driving reimbursement strategies for commercial and government payers. In addition, he directs coverage efforts aligned with internal and external clinical stakeholders to drive policy changes within molecular diagnostics. In his career, Greg held positions on the payor side, creating clinical and ancillary networks under risk and alternative payment models. He holds a B.S. from LSU where he focused on economics and history.

Connolly Steigerwald MS, CGC is a Genomic Science Liaison at Ambry Genetics. She is certified by the American Board of Genetic Counseling and earned her MS in Genetic Counseling from Columbia University in New York City. She previously worked as a clinical genetic counselor within the Lysosomal Storage Disorders Program and Division of Neurogenetics at NYU Langone Health. Her clinical and research interests have spanned lysosomal storage disorders, adult-onset neurodegenerative disease, and predictive genetic testing.  She is an active member of the New York State Genetics Task Force Education Committee. 

Educational Independence and Disclosure Policy

EducateNext is committed to providing independent, objective, and evidence-based educational content. None of the individuals in control of this content—including our planners, reviewers, and approval faculty—have any financial relationships with ineligible companies to disclose. For all educational sessions, speaker-specific disclosures regarding any potential conflicts of interest are required and will always be shared directly with learners at the beginning of their respective presentations.